Bioelectronics Corp (BIEL)

[jimelee]

Evidence From Clinical Trials

Here is just one of the many clinical trials: Warning graphic images of open ulcers.

http://www.bielcorp.com/biel/wp-content/uploads/2013/03/BioElectronics-Chronic-Wound-Case-Series.pdf

Conclusion
The introduction of RecoveryRx PEMF therapy had a significant and positive effect on all the chronic wounds under study. Chronic recalcitrant wounds that had been present for up to 2 years, showed improvements, and in most cases complete healing after the addition of RecoveryRx therapy. A second significant finding was that persistent wound pain was also markedly reduced, usually within two weeks of the beginning of RecoveryRx therapy. Wound healing is a series of complex events that include inflammation, proliferation and maturation. Chronic wounds are stalled in the inflammatory phase of wound healing. The RF energy from RecoveryRx, unlike most wound therapies, works at a cellular level, rapidly resolving edema and breaking the cycle of chronic inflammation. The cells reestablish cell to cell contact and a healthy wound environment forms which allows for cell proliferation and wound repair to progress.

Each of the wounds in the case studies had failed to heal with previous therapies and addition of RecoveryRx PEMF therapy was the only change in the wound treatment protocol. These findings are therefore notable in that the wounds moved into a healing phase and strongly indicate that RecoveryRx is a significant addition to the available wound healing therapies. The ease of use of RecoveryRx, its low cost and compatibility with current conventional therapies and wound dressings demonstrate that RecoveryRx can be widely applied as a first choice wound healing therapy.